JACC. Advances · 2025
Association Between Cardio-Ankle Vascular Index and Heart Failure Outcomes: Insights From a Prospective Multicenter Cohort.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Miyoshi Toru, Shirai Kohji, Horinaka Shigeo, Higaki Jitsuo, Yamamura Shigeo, Saiki Atsuhito, Takahashi Mao, Okura Takafumi, Kotani Kazuhiko, Kubozono Takuro, Yoshioka Ryo, Kihara Hajime, Hasegawa Koji, Satoh-Asahara Noriko, Yamaguchi Osamu, Ito Hiroshi
Аннотация
BACKGROUND: Heart failure (HF) is a substantial public health concern associated with poor prognosis and limited tools for early prediction. Arterial stiffness contributes to the development of HF, particularly with a preserved ejection fraction. The cardio-ankle vascular index (CAVI) is a noninvasive, pressure-independent marker of arterial stiffness. However, its prognostic value in HF remains unclear.
OBJECTIVES: We aimed to evaluate whether CAVI independently predicts HF-related hospitalizations in patients with cardiovascular risk factors and whether it adds prognostic value beyond conventional risk factors.
METHODS: This subanalysis of the multicenter prospective CAVI-J (Prospective Multicenter Study to Evaluate Usefulness of CAVI in Japan) study included 2,932 Japanese adults aged 40 to 74 years with cardiovascular risk factors. Participants were stratified into CAVI tertiles and followed up for a median of 4.9 years. The primary outcomes were HF-related hospitalizations and cardiovascular death. Cox proportional hazards models were used to assess the risk, and the incremental prognostic value was evaluated using global chi-square statistics and reclassification indices.
RESULTS: Primary outcomes were recorded in 32 patients (1.1%). High CAVI (≥9.0) was independently associated with an increased risk (HR: 3.18; 95% CI: 1.09-9.31; P = 0.034). When CAVI was added to a model with known conventional risks, the global chi value increased from 8.82 to 18.77 (P = 0.002), and the net reclassification index was 0.621 (P < 0.001).
CONCLUSIONS: In this exploratory study, elevated CAVI was associated with HF-related hospitalizations and cardiovascular death and modestly improved the risk prediction beyond conventional risk factors. However, the discriminative ability remained limited, and further studies are warranted to establish its clinical utility.
OBJECTIVES: We aimed to evaluate whether CAVI independently predicts HF-related hospitalizations in patients with cardiovascular risk factors and whether it adds prognostic value beyond conventional risk factors.
METHODS: This subanalysis of the multicenter prospective CAVI-J (Prospective Multicenter Study to Evaluate Usefulness of CAVI in Japan) study included 2,932 Japanese adults aged 40 to 74 years with cardiovascular risk factors. Participants were stratified into CAVI tertiles and followed up for a median of 4.9 years. The primary outcomes were HF-related hospitalizations and cardiovascular death. Cox proportional hazards models were used to assess the risk, and the incremental prognostic value was evaluated using global chi-square statistics and reclassification indices.
RESULTS: Primary outcomes were recorded in 32 patients (1.1%). High CAVI (≥9.0) was independently associated with an increased risk (HR: 3.18; 95% CI: 1.09-9.31; P = 0.034). When CAVI was added to a model with known conventional risks, the global chi value increased from 8.82 to 18.77 (P = 0.002), and the net reclassification index was 0.621 (P < 0.001).
CONCLUSIONS: In this exploratory study, elevated CAVI was associated with HF-related hospitalizations and cardiovascular death and modestly improved the risk prediction beyond conventional risk factors. However, the discriminative ability remained limited, and further studies are warranted to establish its clinical utility.